Project Grant R01HL173366
Award Date
1/1/25
Completion Date
11/30/28
Dollars Obligated
$602K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Providence, RI 02903, USA
Similar Awards
This $580,863 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Program (CFDA 93.837), supports research to develop improved cardiac regenerative therapies using engineered human cardiac organoids. The key products and services being delivered include: Optimizing the electrical properties and surface roughness of silicon nanowires incorporated into the cardiac organoids to enhance their interaction with human pluripotent stem...
This federal Project Grant award, totaling $385,381.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The objective is to develop and evaluate injectable, dynamic silk-based hydrogels containing fetal cardiac extracellular matrix (CECM) to promote mechanical stabilization and favorable remodeling of the infarcted ventricular wall following myocardial infarction. The research will assess the impact of...
This federal Project Grant award, with ID R01HL172839, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The award, totaling $361,083.00, aims to investigate how acetylation regulates the subcellular localization and function of the transcriptional cofactor YAP, and explore the potential for combined targeting of the Hippo pathway and YAP acetylation to enhance cardiac regeneration. The research will be...
This $496,367 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop novel approaches for in situ cardiac reprogramming. The key objectives are to: Investigate the mechanism by which a repressor complex inhibits cardiomyocyte gene expression, including testing if knockdown of individual repressors can recapitulate the effects of combined knockdown. Determine if targeting the repressor complex...
This $693,261 R01 project grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will investigate the Hippo-YAP signaling pathway in cardiac regenerative repair. The objectives are to gain insights into gene therapy strategies that knock down Hippo signaling in cardiac tissue following myocardial infarction, with the goal of improving cardiac function in mouse models of ischemic heart failure. Key activities include evaluating the YAP-mediated...
This $653,854 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The purpose of the grant is to study the impact of cardiomyocyte-selective modulation of natriuretic peptide signaling pathways on cardiomyopathy progression and ventricular arrhythmia susceptibility in preclinical models. The specific aims are to: 1) Define how cardiomyocyte-specific modulation of PKG1 activity modifies cardiomyopathy...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
The U.S. National Heart, Lung, and Blood Institute (NHLBI) awarded a $498,991.40 Project Grant to the University of Arkansas under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The funding supports the development of microphysiological systems to study hypoxic cardiac injury resulting from acute myocardial infarction and ischemia-reperfusion injury. The research aims to engineer microfluidic devices to precisely control oxygen levels and investigate how oxygen...
This $2,352,138 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to improve the treatment of acute myocardial infarction (AMI) and prevent heart failure (HF). The research aims to model and experimentally validate cell-specific signaling of the LRP1 receptor in AMI, which is known to play a protective role in ischemia-reperfusion injury. Specific objectives include: 1) Expanding and...
This $655,636 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will fund research conducted by the Texas Heart Institute to investigate the mechanisms of heart failure in patients with single ventricle congenital heart disease. The research objectives are to: 1) Examine the molecular drivers of cardiac fibroblast senescence in single ventricle heart failure patients, 2) Investigate the metabolic remodeling of cardiac...